Initial Data on Clinical Use of Generic Romiplostim for Second-Line and Subsequent Therapy of Immune Thrombocytopenia in India
Introduction: Over 50% of adults with immune thrombocytopenia (ITP) require second-line therapy after steroids, but these options are plagued by low rates of response, which are often delayed by 2–3 months. Romiplostim is a thrombopoietin receptor agonist (TPO-RA) that has shown significant efficacy...
Saved in:
| Main Authors: | Suvir Singh, Komalpreet Kaur |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | Indian Journal of Medical Specialities |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/injms.injms_105_20 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
by: Nichola Cooper, et al.
Published: (2025-03-01) -
Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01) -
Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01) -
Valproate-induced thrombocytopenia
by: N. V. Izmozherova, et al.
Published: (2024-04-01) -
Description of a Case Series of Genetic Thrombocytopenia Diagnosed in a Hematology Service of a Reference Hospital in Bogotá, Colombia Between 2000-2021 and a Narrative Review of Literature
by: Casas Patarroyo, Claudia Patricia, et al.
Published: (2025-07-01)